Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Overall Survival

A measure of the time until death from any cause.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
BACKGROUND In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in… Expand
Is this relevant?
Review
2019
Review
2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
BACKGROUND Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Review
2019
Review
2019
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
BACKGROUND Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2019
Review
2019
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
Importance Patients with locally advanced pancreatic cancer have historically poor outcomes. Evaluation of a total neoadjuvant… Expand
Is this relevant?
Review
2019
Review
2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
BACKGROUND Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression… Expand
  • figure 1
  • table 2
  • figure 3
Is this relevant?
Review
2019
Review
2019
Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities
BACKGROUND A subset of patients treated with immune checkpoint inhibitors experience an accelerated tumor growth rate (TGR) in… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Review
2019
Review
2019
Using adaptive magnetic resonance image‐guided radiation therapy for treatment of inoperable pancreatic cancer
Abstract Background Adaptive magnetic resonance imaging‐guided radiation therapy (MRgRT) can escalate dose to tumors while… Expand
  • table 1
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Improved overall survival in melanoma with combined dabrafenib and trametinib.
BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Improved survival with ipilimumab in patients with metastatic melanoma.
BACKGROUND An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
PURPOSE A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE